Jignesh Patel, MD
Advanced Heart Failure and Transplant Cardiology · Beverly Hills, CANPI 1104914944
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $133,035 of the $176,317 with a category attached, or 75.5%. Pfizer accounts for 69.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $64,758 and has fallen 100.0% since, to $18 in 2024.
Across 155 payments — averaging $1137.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$123K
- Alnylam Pharmaceuticals Inc.$37K
- Akcea Therapeutics, Inc.$17K
- AstraZeneca$150
- Novartis$96
- Takeda Pharmaceuticals U.S.A., Inc.$66
- plus $68 from 2 others
Across 58 payments — averaging $6899.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$198K
- Pfizer$123K
- Boehringer Ingelheim$61K
- AstraZeneca$9K
- Boehringer Ingelheim Pharma GmbH & Co.kg$5K
- Novartis$4K
What the payments were for
- Consulting fees$27,69016%
- Speaking & faculty fees$133,03575%
- Travel & lodging$12,1507%
- Food & beverage$3,4412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 94 | $122,605 |
| Alnylam Pharmaceuticals Inc. | 39 | $36,628 |
| Akcea Therapeutics, Inc. | 16 | $16,703 |
| AstraZeneca | 1 | $150 |
| Novartis | 1 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $66 |
| Abbott | 2 | $51 |
| Gilead | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$176,317 in reported general payments places this provider in the 85th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 14 | $7,619 |
| Carvedilol | 13 | $179 |
| Rosuvastatin Calcium | 12 | $125 |
| Pantoprazole Sodium | 14 | $105 |
| Pravastatin Sodium | 19 | $95 |
| Amlodipine Besylate | 19 | $60 |
| Losartan Potassium | 11 | $59 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $27 |
| Ezetimibe | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Beverly Hills
- Lily SternBeverly Hills$32K
- Jaime MoriguchiBeverly Hills$20K
- Michele HamiltonBeverly Hills$17K
- Kambiz GhafourianBeverly Hills$9K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.